Biomaterial 3D collagen I gel culture model: A novel approach to investigate tumorigenesis and dormancy of bladder cancer cells induced by tumor microenvironmentYaqi Qiu, Qiang Wei, Lina Gong et al.|Biomaterials|2020Cited by 44
CD93 orchestrates the tumor microenvironment and predicts the molecular subtype and therapy response of bladder cancerXiaonan Zheng, Qiang Wei, Ping Tan et al.|Computers in Biology and Medicine|2022Cited by 11
Real-world study of chemotherapy plus immunotherapy versus chemotherapy alone as neoadjuvant treatment guided bladder-sparing therapy for localized muscle-invasive bladder cancer.Yali Shen, Tianhai Lin, Peng Zhang et al.|Journal of Clinical Oncology|2022Cited by 7
A multi-center phase Ib/II study of RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2 positive locally advanced muscle-invasive urothelial bladder cancer (Hope-03).Feng Wen, Yali Shen, Mengni Zhang et al.|Journal of Clinical Oncology|2025Cited by 3
Long-term results of a phase 2 study of neoadjuvant chemotherapy combined with tislelizumab followed by radiotherapy for bladder-preserving treatment in selected high-risk/locally advanced muscle invasive urothelial bladder cancer (HOPE-02).Feng Wen, Yali Shen, Ping Tan et al.|Journal of Clinical Oncology|2025Cited by 2